Medicare GLP-1 Bridge Program 2026: How Eligible Medicare Patients May Access Wegovy®, Zepbound®, and Foundayo® for $50 Per Month

Medicare Expands Access to Weight Loss Medications

This demonstration program is designed to improve access to highly effective anti-obesity medications for qualifying Medicare patients who meet specific eligibility requirements.

The program represents one of the most significant expansions of Medicare coverage for obesity treatment in recent years and may allow many patients to obtain medications that were previously unaffordable.

What Is the Medicare GLP-1 Bridge Program?

The Medicare GLP-1 Bridge Program is a CMS demonstration initiative designed to provide eligible Medicare beneficiaries with access to covered GLP-1 medications used to reduce excess body weight and maintain weight reduction.

Coverage is not automatic. Beneficiaries must meet Medicare eligibility requirements, clinical criteria, and prior authorization requirements established by CMS and participating Medicare Part D plans.

Who May Be Eligible?

• Be enrolled in Medicare Part D.
• Be enrolled in an eligible Medicare prescription drug plan.
• Use a covered GLP-1 medication for weight management.
• Meet Medicare GLP-1 Bridge clinical criteria.
• Meet prior authorization requirements.

Eligible Plan Types

• Standalone Prescription Drug Plans (PDPs)
• Medicare Advantage Prescription Drug Plans (MA-PD)
• HMO Plans
• HMOPOS Plans
• Local PPO Plans
• Regional PPO Plans
• Special Needs Plans (SNPs)
• Employer Group Waiver Plans (EGWPs)
• LI NET Program Participants
• Certain Dually Eligible Beneficiaries

Which Medications Are Included?

Wegovy®

• Wegovy® Injection Pens
• Wegovy® Tablets

Zepbound®

• Zepbound® KwikPen®

Foundayo®

Foundayo® was added to the program following FDA approval.

How Do Patients Obtain Coverage?

Patients cannot enroll themselves directly into the program.

1. Schedule an appointment with a healthcare provider.
2. Determine eligibility for treatment.
3. Receive a prescription for an eligible GLP-1 medication.
4. Have the provider submit a prior authorization request.

Prior authorization requests may be submitted electronically or by fax using Medicare GLP-1 Bridge documentation.

Important Timeline

June 2026

• Additional provider guidance released.
• Prior authorization instructions released.
• Program forms released.
• Operational details released.

July 1, 2026

The Medicare GLP-1 Bridge Program officially begins.

Prior authorization requests will not be accepted or processed before July 1, 2026.

Why This Matters

• Type 2 Diabetes
• Heart Disease
• Stroke
• Sleep Apnea
• Osteoarthritis
• Fatty Liver Disease
• Certain Cancers

GLP-1 medications have demonstrated significant weight loss benefits and may help improve long-term health outcomes when combined with healthy nutrition, exercise, and ongoing medical supervision.

How James Whynot MD Can Help

• Determine eligibility for GLP-1 therapy.
• Review Medicare requirements.
• Evaluate weight loss goals.
• Discuss medication options.
• Provide ongoing follow-up and monitoring.

← Back to Blog